Valuation: Voyager Therapeutics, Inc.

Market Cap 165M 147M 137M 125M 235M 15.9B 239M 1.66B 642M 8.1B 620M 607M 26.01B P/E 2026 *
-1.59x
P/E 2027 * -2.13x
Enterprise Value 46.84M 41.6M 38.9M 35.45M 66.74M 4.51B 67.66M 471M 182M 2.3B 176M 172M 7.38B EV / Sales 2026 *
2.31x
EV / Sales 2027 * 0.61x
Free-Float
85.16%
Yield 2026 *
-
Yield 2027 * -
1 day+2.05%
1 week-2.68%
Current month+1.68%
1 month-20.55%
3 months-24.31%
6 months-31.70%
Current year-30.66%
1 week 2.58
Extreme 2.58
2.79
1 month 2.58
Extreme 2.58
3.58
Current year 2.58
Extreme 2.58
5.48
1 year 2.58
Extreme 2.58
5.55
3 years 2.58
Extreme 2.58
11.72
5 years 2.46
Extreme 2.46
14.34
10 years 2.46
Extreme 2.46
31.91
Manager TitleAgeSince
Chief Executive Officer 68 2022-03-21
Chief Tech/Sci/R&D Officer 56 2018-10-31
Director of Finance/CFO 55 2024-03-31
Director TitleAgeSince
Director/Board Member 71 2013-12-31
Director/Board Member 73 2015-09-16
Director/Board Member 70 2017-01-04
Date Insider Type Main position Quantity % Market Cap. Importance
6/9/26 Free

Chairman

30,000 0.0497%
6/9/26 Free

Director

30,000 0.0497%
5/8/26 Other

Controller/Auditor

115,249 0.1911%
Change 5-day change 1-year change 3-year change Capi.($)
+2.05%-2.68%-41.77%-62.36% 165M
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+80.21% 60.14B
-2.54%-1.65%+4.86%+33.32% 48.15B
-2.56%-4.87%+28.39%+34.95% 44.25B
+0.74%+3.88%+352.71%+693.33% 43.99B
-1.90%+0.08%+7.49%+101.83% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-3.87%-9.32%-25.16%+334.45% 24.93B
Average +0.42%+1.11%+45.11%+138.39% 39.7B
Weighted average by Cap. +0.41%+1.83%+58.98%+151.79%

Financials

2026 *2027 *
Net sales 20.28M 18.01M 16.84M 15.35M 28.89M 1.95B 29.29M 204M 78.87M 994M 76.13M 74.47M 3.19B 46.58M 41.38M 38.69M 35.26M 66.38M 4.49B 67.29M 468M 181M 2.28B 175M 171M 7.34B
Net income -106M -94.29M -88.17M -80.35M -151M -10.22B -153M -1.07B -413M -5.21B -399M -390M -16.72B -88.66M -78.75M -73.65M -67.11M -126M -8.54B -128M -891M -345M -4.35B -333M -326M -13.96B
Net Debt -118M -105M -98.26M -89.54M -169M -11.39B -171M -1.19B -460M -5.8B -444M -435M -18.63B -136M -121M -113M -103M -195M -13.14B -197M -1.37B -531M -6.69B -512M -501M -21.5B
Logo Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.
Employees
141
Date Price Change Volume
26-10-01 US$2.725 +1.68% 361,179
26-09-30 US$2.680 +1.52% 598,785
26-09-29 US$2.640 -2.22% 628,608
26-09-28 US$2.700 +0.75% 646,077
26-09-25 US$2.680 -4.29% 721,295
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
2.680USD
Average target price
14.89USD
Spread / Average Target
+455.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VYGR Stock